Study of Tau Imaging With the Use of [18F]MK-6240 Tracer

Enrolling by invitationOBSERVATIONAL
Enrollment

200

Participants

Timeline

Start Date

March 1, 2021

Primary Completion Date

April 1, 2025

Study Completion Date

June 1, 2025

Conditions
Alzheimer Disease
Interventions
DRUG

MK 6240

"PET tracer, \[18F\]MK-6240 (an\[18F\]tau imaging agent,CerveauTechnologies)that has high affinity for the human phosphorylated tau deposits in AD brain offers new opportunities to investigate tau pathology.(Hostetler, Walji et al. 2016, Lohith, Bennacef et al. 2016, Walji, Hostetler et al. 2016, Lohith, Bennacef et al. 2017, Neelamegam, Yokell et al. 2017).We will evaluate this imaging agent in individuals from families with a known Autosomal Dominant Alzheimer's Disease (ADAD) mutation.~The planned dosage for \[18F\]MK-6240 is a single intravenous bolus injection of 185 MBq (5.0 mCi) in a large peripheral vein followed by a 10 mL normal saline (0.9% NaCl) flush."

Trial Locations (1)

63110

Washington University School of Medicine, St Louis

All Listed Sponsors
lead

Tammie L. S. Benzinger, MD, PhD

OTHER